EARNEST Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

EARNEST Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-48	Closed	-$39.5K	–	920
2023 Q3	$39.5K	Hold	48	–	–	﹤0.01%	390
2023 Q2	$34.5K	Hold	48	–	–	﹤0.01%	392
2023 Q1	$39.4K	Hold	48	–	–	﹤0.01%	366
2022 Q4	$34.6K	Hold	48	–	–	﹤0.01%	382
2022 Q3	$33K	Hold	48	–	–	﹤0.01%	372
2022 Q2	$28K	Hold	48	–	–	﹤0.01%	404
2022 Q1	$34K	Hold	48	–	–	﹤0.01%	388
2021 Q4	$30K	Hold	48	–	–	﹤0.01%	419
2021 Q3	$29K	Hold	48	–	–	﹤0.01%	413
2021 Q2	$27K	Hold	48	–	–	﹤0.01%	422
2021 Q1	$23K	Hold	48	–	–	﹤0.01%	442
2020 Q4	$23K	Hold	48	–	–	﹤0.01%	423
2020 Q3	$27K	Buy	48 +12	+33%	+$7.28K	﹤0.01%	364
2020 Q2	$22K	Hold	36	–	–	﹤0.01%	385
2020 Q1	$18K	Hold	36	–	–	﹤0.01%	403
2019 Q4	$14K	Hold	36	–	–	﹤0.01%	516
2019 Q3	$10K	Hold	36	–	–	﹤0.01%	586
2019 Q2	$11K	Hold	36	–	–	﹤0.01%	561
2019 Q1	$15K	Hold	36	–	–	﹤0.01%	492
2018 Q4	$13K	Hold	36	–	–	﹤0.01%	486
2018 Q3	$15K	Hold	36	–	–	﹤0.01%	490
2018 Q2	$12K	Hold	36	–	–	﹤0.01%	531
2018 Q1	$12K	Hold	36	–	–	﹤0.01%	527
2017 Q4	$14K	Buy	+36	New	+$14.6K	﹤0.01%	486
2017 Q1	–	Sell	-36	Closed	-$13K	–	757
2016 Q4	$13K	Buy	+36	New	+$13.7K	﹤0.01%	473

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

EARNEST Partners's REGN Position: Q4 2023 in Review

EARNEST Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 48 shares — an estimated $39.5K sold.

EARNEST Partners first reported a position in REGN in Q4 2016 and held it in 25 quarters. The position peaked at $39.5K in Q3 2023. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

EARNEST Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 48 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $39.5K.
EARNEST Partners first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 25 quarters.
EARNEST Partners's Regeneron Pharmaceuticals position peaked at $39.5K in Q3 2023.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.